[Form 4] ROCKWELL MEDICAL, INC. Insider Trading Activity

Rhea-AI Filing Summary

Insider sale under a 10b5-1 plan: Mark Strobeck, President and CEO and a director of Rockwell Medical, sold 6,926 shares of Rockwell Medical common stock on 10/01/2025 at a reported price of $1.19 per share.

After the transaction, the filing reports Mr. Strobeck beneficially owns 330,826 shares, held directly. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted May 30, 2024, and the filer offers to provide details of the number of shares and prices upon request.

Positive

• Sale executed under a Rule 10b5-1 plan, which provides pre-established trading parameters and reduces appearance of opportunistic timing
• Clear disclosure of post-transaction beneficial ownership (330,826 shares), supporting transparency

Negative

• Insider sale of shares (6,926 shares at $1.19) could be perceived negatively by some investors despite being under a trading plan

Insights

Financial Analyst

TL;DR: CEO sold a small block under a pre-established 10b5-1 plan; transaction is transparent and likely routine.

The 6,926-share sale at $1.19 is clearly disclosed and executed under a Rule 10b5-1 plan, reducing the likelihood the sale was motivated by undisclosed company material nonpublic information. Post-sale direct ownership of 330,826 shares remains disclosed, which preserves transparency around insider holdings. The absolute size of the transaction appears modest relative to typical insider stakes, suggesting limited immediate impact on valuation metrics. Investors seeking material signals should request the full execution details as offered in the filing.

Corporate Governance Expert

TL;DR: Proper procedural safeguards observed: sale under a documented 10b5-1 plan and signed by an attorney-in-fact.

The filing notes the 10b5-1 plan adoption date (May 30, 2024) and includes an attorney-in-fact signature, indicating governance processes for insider trading were followed. This strengthens procedural compliance and disclosure practices. The report gives the post-transaction direct ownership figure, which supports shareholder transparency. No indication of amendments or other governance issues appear in the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Strobeck Mark

(Last) (First) (Middle)

30142 WIXOM ROAD

(Street)

WIXOM MI 48393

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKWELL MEDICAL, INC. [ RMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		S(1)		6,926	D	$1.19	330,826	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. The price reported above reflects the sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Megan Timmins, Attorney-in-fact for Mark Strobeck	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

When did the RMTI insider transaction occur?

The transaction date was 10/01/2025.

How many Rockwell Medical (RMTI) shares did Mark Strobeck sell and at what price?

Mr. Strobeck sold 6,926 shares at a reported price of $1.19 per share.

How many Rockwell Medical shares does the reporting person own after the sale?

The filing reports 330,826 shares beneficially owned following the reported transaction.

Was the sale part of a 10b5-1 plan and when was it adopted?

Yes. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted May 30, 2024.

Who signed the Form 4 on behalf of Mark Strobeck?

The form was signed by Megan Timmins, Attorney-in-fact for Mark Strobeck on 10/01/2025.